RxDoctor Payments Data

Matthew Mooney

Optometrist · Mt Washington, KYNPI 1518166610

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (54.1%), food and beverage and education — rather than concentrated in one kind of arrangement. Optos, Inc. accounts for 62.7% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $3,475 and has fallen 96.4% since, to $126 in 2025. Among optometrist clinicians in KY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,555in general payments, 2019–2025

Across 56 payments — averaging $81.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Optos, Inc.$3K
  • Optos PLC$434
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$293
  • LKC Technologies, Inc.$252
  • Bausch & Lomb Americas Inc.$220
  • ABB Con-cise Optical Group LLC$151
  • plus $347 from 6 others

What the payments were for

  • Travel & lodging$2,46554%
  • Food & beverage$1,73038%
  • Education$2395%
  • Gifts$431%
  • Entertainment$782%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,555 in reported general payments places this provider in the 90th percentile of 712 optometrist providers in Kentucky.

See all optometrist providers in Kentucky

Medicare billing

Part B allowed, 2024
$47,610
Medicare patients
247
Services billed
3,400

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost31$9,672
Prednisolone Acetate46$1,609
Fluorometholone24$1,346
Latanoprost67$571
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha35$396
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat21$236
Dorzolamide Hcl18$199
Brimonidine Tartrate14$80
Timolol Maleate13$46

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$71$9,67231 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 712 optometrist providers in Kentucky.

Other optometrist in Mt Washington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →